title: Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) with E250K mutation in CD2BP1 gene treated with the tumor necrosis factor inhibitor adalimumab.
authors.forename: H
authors.initials: H
authors.lastname: Lee
authors.forename: S H
authors.initials: SH
authors.lastname: Park
authors.forename: S K
authors.initials: SK
authors.lastname: Kim
authors.forename: J Y
authors.initials: JY
authors.lastname: Choe
authors.forename: J S
authors.initials: JS
authors.lastname: Park
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy* / Q000235:genetics*; D000068879:Adalimumab; D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics*; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001170:Arthritis, Infectious / Q000188:drug therapy* / Q000235:genetics*; D003598:Cytoskeletal Proteins / Q000235:genetics*; D006801:Humans; D008297:Male; D017354:Point Mutation / Q000235:genetics*; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000235:genetics*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D003598:Cytoskeletal Proteins; C486382:PSTPIP1 protein, human; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab